Patent ID: 8765713
Filing Date: 2014-07-01
Classification: A61K,A61P,G01N

Abstract:
1. A method for determining sensitivity of a subject undergoing therapy for colorectal cancer with 5-fluorouracil or a salt thereof, the method comprising: obtaining a sample (A) from the subject after being administered 5-fluorouracil of a salt thereof, identifying by mass spectrometry at least one peak selected from the group consisting of a peak at m/z of 5,300 to 5,400, a peak at m/z of 6,130 to 6,230, a peak at m/z of 7,000 to 7,080, a peak at m/z of 11,020 to 11,120, a peak at m/z of 17,100 to 17,270, a peak at m/z of 18,290 to 18,470, a peak at m/z of 24,660 to 24,750, a peak at m/z of 35,980 to 36,290, a peak at m/z of 7,840 to 7,920, and a peak at m/z of 9,100 to 9,200; comparing the at least one peak intensity to a corresponding peak measured the same way from a sample (B) obtained from the subject prior to being administered 5-fluorouracil or a salt thereof and/or a corresponding peak of a predetermined standard peak intensity (C), and if the intensity of at least one of the peaks of sample (A) selected from the group consisting of a peak at m/z of 5,300 to 5,400, a peak at m/z of 6,130 to 6,230, a peak at m/z of 7,000 to 7,080, a peak at m/z of 11,020 to 11,120, a peak at m/z of 17,100 to 17,270, a peak at m/z of 18,290 to 18,470, a peak at m/z of 24,660 to 24,750, and a peak at m/z of 35,980 to 36,290 is higher than the intensity of the corresponding at least one peak at m/z of sample (B) and/or (C) ceasing administration of 5-fluorouracil or a salt thereof, if the intensity of at least one of the peaks of sample (A) selected from the group consisting of a peak at m/z of 5,300 to 5,400, a peak at m/z of 6,130 to 6,230, a peak at m/z of 7,000 to 7,080, a peak at m/z of 11,020 to 11,120, a peak at m/z of 17,100 to 17,270, a peak at m/z of 18,290 to 18,470, a peak at m/z of 24,660 to 24,750, and a peak at m/z of 35,980 to 36,290 is about the same or is lower than the intensity of the corresponding at least one peak at m/z of sample (B) and/or (C) continuing administration of 5-fluorouracil or a salt thereof, if the intensity of at least one of the peaks of sample (A) selected from the group consisting of a peak at m/z of 7,840 to 7,920, and a peak at m/z of 9,100 to 9,200 is lower than the intensity of the corresponding at least one peak at m/z of sample (B) and/or (C) continuing administration of 5-fluorouracil or a salt thereof, or if the intensity of at least one of the peaks of sample (A) selected from the group consisting of a peak at m/z of 7,840 to 7,920, and a peak at m/z of 9,100 to 9,200 is about the same or is higher than the intensity of the corresponding at least one peak at m/z of sample (B) and/or (C) ceasing administration of 5-fluorouracil or a salt thereof.